Figure 5.

Oral gavage of vehicle, afatinib, dacomitinib, osimertinib, poziotinib, mobocertinib according to the dosing schedule (A) in a p.L747P-mutant patient-derived xenograft model (B). EGFR TKIs for the antitumor tumor activity (C), tumor volume (D), tumor inhibition rate (E) and mice body weight (F) in p.L747P-mutant xenograft mouse model. Phosphorylated EGFR, and its downstream molecules phosphorylated ERK and phosphorylated AKT under inhibition of different EGFR TKIs by IHC analysis (G). *P < 0.05; **P < 0.01; ***P < 0.001.